Uncategorized Archives

12 Aug Bio-Me has been selected as one of the newest companies to join Nordic Mentor Network For Entrepreneurship – NOME

Posted at 10:28h in Uncategorized

Bio-Me has been selected to join the Nordic Mentor Network For Entrepreneurship (NOME), gaining access to a network of experienced life science mentors as it scales its Precision Microbiome Profiling (PMP™) platform and explores new applications in women's health and reproductive care....

23 Mar Phase 2 FMT‑LUMINate trial meets primary endpoint and points to “loss of deleterious taxa” as a key mechanism in microbiome‑enabled immunotherapy

Posted at 11:06h in Uncategorized

Immune checkpoint inhibitors (ICIs) have improved outcomes in NSCLC and melanoma, yet many patients still show primary resistance. The phase 2, multicenter, open‑label FMT‑LUMINate trial evaluated whether a single oral FMT from a healthy donor, administered before ICI initiation, could enhance first‑line treatment efficacy. Clinical activityNSCLC cohort...

12 Nov Press Release: Bio-Me AS Appoints Dr. Davide Manissero to Board of Directors to Accelerate Women’s Health Diagnostics Strategy

Posted at 08:53h in Uncategorized

Bio-Me developing next-generation, microbiome based molecular diagnostic in Women's Health...

03 Jun Press Release: Bio-Me and Pelvic Relief partners to launch Advanced Vaginal Microbiome Test to Transform Women’s Health

Posted at 06:53h in Uncategorized

With Precision Microbiome Profiling Bio-Me aims to help healthcare professionals personalize care and empower women to make informed health decisions ...

17 Sep Cell publication: Precision Microbiome Profiling (PMP™) demonstrates it diagnostic potential in groundbreaking work conducted at Gustave Roussy Cancer Institute

Posted at 09:41h in Uncategorized

TOPOSCORE, a bacterial signature for reliably predicting response to immune checkpoint inhibitor treatment in cancer patients, has been successfully validated on PMP™, demonstrating the clinical utility of Bio-Me’s proprietary platform. ...

12 Sep Press Release: Bio-Me AS Announces Appointment of Arne Materna as Co-CEO alongside Dr. Warren Flood

Posted at 15:04h in Uncategorized

Dr. Arne Materna has been appointed Co-CEO as of July 1st, 2024 to strengthen the company’s capitalization and continued commercial growth....

07 Sep Bio-Me selected as a partner in the PREVALUNG EU program developing predictive biomarkers associated with lung cancer risk

Posted at 08:52h in Uncategorized

The PREVALUNG EU program aims to implement cancer risk stratification tools and personalized interventions to intercept lung cancer in cardiovascular patients. Bio-Me’s Precision Microbiome Profiling (PMP™) was chosen for high-throughput gut microbiome profiling....

27 Apr Bio-Me’s technology used for identifying bacteria associated with appendicular lean mass in a Nature Communications publication

Posted at 08:57h in Uncategorized

PMP™ was used in a recent study to identify gut microbial species that are directly associated with appendicular lean mass and bone mineral density. More than 5000 fecal samples from the HUNT Biobank in Norway were analyzed with PMP™....

05 Aug Bio-Me´s PMP™ platform demonstrates its diagnostic and prognostic applicability in pediatric IBD

Posted at 10:23h in Uncategorized

PMP™ was used in a recent study to explore the gut microbiome of children with inflammatory bowel disease (IBD), symptomatic non-IBD, and healthy children. Diagnostic, Phenotype and Prognostic Indexes were constructed based on PMP™ data with very good discriminating properties....

04 Jul Bio-Me strengthens its international commercial team with key hire

Posted at 09:28h in Uncategorized

Bio-Me has employed Dr. Anne-Grethe Reichelt as part of the company’s plan to widen commercial adoption of their existing product portfolio and launch new products under development. ...

12 Aug Bio-Me has been selected as one of the newest companies to join Nordic Mentor Network For Entrepreneurship – NOME

23 Mar Phase 2 FMT‑LUMINate trial meets primary endpoint and points to “loss of deleterious taxa” as a key mechanism in microbiome‑enabled immunotherapy

12 Nov Press Release: Bio-Me AS Appoints Dr. Davide Manissero to Board of Directors to Accelerate Women’s Health Diagnostics Strategy

03 Jun Press Release: Bio-Me and Pelvic Relief partners to launch Advanced Vaginal Microbiome Test to Transform Women’s Health

17 Sep Cell publication: Precision Microbiome Profiling (PMP™) demonstrates it diagnostic potential in groundbreaking work conducted at Gustave Roussy Cancer Institute

12 Sep Press Release: Bio-Me AS Announces Appointment of Arne Materna as Co-CEO alongside Dr. Warren Flood

07 Sep Bio-Me selected as a partner in the PREVALUNG EU program developing predictive biomarkers associated with lung cancer risk

27 Apr Bio-Me’s technology used for identifying bacteria associated with appendicular lean mass in a Nature Communications publication

05 Aug Bio-Me´s PMP™ platform demonstrates its diagnostic and prognostic applicability in pediatric IBD

04 Jul Bio-Me strengthens its international commercial team with key hire

Oslo Science Park

Gaustadalléen 21

N-0349 Oslo

Norway

Tel: +47 21 09 03 02

Email:

Read Our Privacy Policy

12 Aug Bio-Me has been selected as one of the newest companies to join Nordic Mentor Network For Entrepreneurship – NOME

23 Mar Phase 2 FMT‑LUMINate trial meets primary endpoint and points to “loss of deleterious taxa” as a key mechanism in microbiome‑enabled immunotherapy

12 Nov Press Release: Bio-Me AS Appoints Dr. Davide Manissero to Board of Directors to Accelerate Women’s Health Diagnostics Strategy

03 Jun Press Release: Bio-Me and Pelvic Relief partners to launch Advanced Vaginal Microbiome Test to Transform Women’s Health

17 Sep Cell publication: Precision Microbiome Profiling (PMP™) demonstrates it diagnostic potential in groundbreaking work conducted at Gustave Roussy Cancer Institute

12 Sep Press Release: Bio-Me AS Announces Appointment of Arne Materna as Co-CEO alongside Dr. Warren Flood

07 Sep Bio-Me selected as a partner in the PREVALUNG EU program developing predictive biomarkers associated with lung cancer risk

27 Apr Bio-Me’s technology used for identifying bacteria associated with appendicular lean mass in a Nature Communications publication

05 Aug Bio-Me´s PMP™ platform demonstrates its diagnostic and prognostic applicability in pediatric IBD

04 Jul Bio-Me strengthens its international commercial team with key hire

Oslo Science Park

Gaustadalléen 21

N-0349 Oslo

Norway

Tel: +47 21 09 03 02

Email: info@bio-me.com

Read Our Privacy Policy

Email: